Filtered By:
Condition: Multiple Sclerosis
Education: Study
Therapy: Pain Management

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 33 results found since Jan 2013.

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Robot-Assisted Therapy in Upper Extremity Hemiparesis: Overview of an Evidence-Based Approach
Conclusion Robotic therapy has matured and represents an embodiment of a paradigm shift in neurorehabilitation following a stroke: instead of focusing on compensation, it affords focus in ameliorating the impaired limb in line with concepts of neuroplasticity. This technology-based treatment provides intensity, interactivity, flexibility, and adaptiveness to patient's performance and needs. Furthermore, it increases the productivity of rehabilitation care. Of course, efficiency must be discussed within a local perspective. For example, following the cost containment shown in the VA ROBOTICS study (46), the UK Nati...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Oversleeping: The Effects and Health Risks of Sleeping Too Much
This article originally appeared on the Amerisleep blog. Rosie Osmun is the Creative Content Manager at Amerisleep, a progressive memory foam mattress brand focused on eco-friendly sleep solutions. Rosie writes more posts on the Amerisleep blog about the science of sleep, eco-friendly living, leading a healthy lifestyle and more. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - January 29, 2016 Category: Consumer Health News Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

E-248 Postpartum vertebral artery dissections: a report of 7 cases and literature review
ConclusionA limited cohort of 33 ppVADs exist in the literature. This study contributes 7 additional cases and suggests that, despite heterogenous management of ppVAD, the resulting outcomes were favorable.Disclosures V. Lazarov: None. A. Monteiro: None. F. Almayman: None. M. Waqas: None. J. Cappuzzo: None. E. Levy: None. A. Siddiqui: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lazarov, V., Monteiro, A., Almayman, F., Waqas, M., Cappuzzo, J., Levy, E., Siddiqui, A. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions.
CONCLUSIONS: Spasticity is associated with worse health status, however its relationship with overall QOL is not established. The relationship between spasticity and QOL is confounded by other impairments and requires multivariate analysis. Implications for Rehabilitation Effective management of spasticity may result in significant improvements in HRQOL. It is important to address multiple factors in the management of spasticity including pain, bladder problems, fatigue and sleep, as the interplay of these may have significant negative effects on HRQOL. Clinician-administered methods for measuring spasticity, such as the A...
Source: Disability and Rehabilitation - December 29, 2015 Category: Rehabilitation Authors: Milinis K, Young CA, Trajectories of Outcome in Neurological Conditions (TONiC) study Tags: Disabil Rehabil Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Transcranial Direct Current Stimulation for the Management of Neuropathic Pain: A Narrative Review
CONCLUSION: The results of the included studies suggest that tDCS may be beneficial in treating patients with NP due to stroke, spinal cord injury, multiple sclerosis, and trigeminal neuralgia. Further studies are recommended to validate the efficacy of tDCS in treating other types of NPs.PMID:34554695
Source: Pain Physician - September 23, 2021 Category: Anesthesiology Authors: Seoyon Yang Min Cheol Chang Source Type: research

157 E-Books New to JEFFLINE
Scott Library added these 157 e-books to the growing collection in May and June: Accurate Results in the Clinical Laboratory Adult Emergency Medicine Adult-Gerontology and Family Nurse Practitioner Certification Examination (4th ed.) Advanced Assessment: Interpreting Findings and Formulating Differential Diagnoses (2nd ed.) Advancing Your Career: Concepts of Professional Nursing (5th ed.) Arrhythmia Essentials Atlas of Advanced Operative Surgery Atlas of Clinical Neurology (3rd ed.) Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches Atlas of Human Infectious Diseases Atlas of No...
Source: What's New on JEFFLINE - June 25, 2013 Category: Databases & Libraries Authors: Gary Kaplan Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news

Levetiracetam for neuropathic pain in adults.
CONCLUSIONS: The amount of evidence for levetiracetam in neuropathic pain conditions was very small and potentially biased because of the methods of analysis used in the studies. There was no indication that levetiracetam was effective in reducing neuropathic pain, but it was associated with an increase in participants who experienced adverse events and who withdrew due to adverse events. PMID: 25000215 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - July 7, 2014 Category: Journals (General) Authors: Wiffen PJ, Derry S, Moore RA, Lunn MP Tags: Cochrane Database Syst Rev Source Type: research

Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide,  nearly44 million  people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the  top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news

Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report
Conclusion—Ketamine may be an alternative treatment for resistant depression and may have a special use in patients with multiple sclerosis. Introduction Depression is a frequent finding in patients with multiple sclerosis (MS), with the lifetime prevalence rates for major depressive disorder (MDD) ranging from 36 to 54 percent, more than twice of that in the general population.[1] Even with advances in pharmacological options for treating depression, an estimated 33 to 66 percent of patients with MDD in the general population do not respond to the first antidepressant, and a reported 15 to 33 percent of patients do not ...
Source: Innovations in Clinical Neuroscience - February 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Depression Multiple Sclerosis Neurology Psychiatry Psychopharmacology Electroconvulsive therapy Ketamine major depressive disorder treatment-resistant depression Source Type: research

Uses of Electrical Stimulation for the Rehabilitation of People with Multiple Sclerosis: A Review
AbstractPurpose of ReviewThe aim of this review is to summarize the literature regarding use of electrical stimulation in the rehabilitation of people with multiple sclerosis (MS).Recent FindingsWhile significant work has been done to study the effect of electrical stimulation in stroke and spinal cord injury, few studies have looked at degenerative diseases including MS.SummaryTo date, limited high-quality evidence is available to demonstrate definitive benefits of electrical stimulation. This review considers the potential benefits of electrical stimulation for the management of foot drop, pain, spasticity, weakness, and...
Source: Current Physical Medicine and Rehabilitation Reports - July 25, 2017 Category: Rehabilitation Source Type: research

Long-Term Outcomes in the Management of Central Neuropathic Pain Syndromes: A Prospective Observational Cohort Study.
CONCLUSION: Patients with central neuropathic pain syndromes managed in tertiary care centers were less likely to achieve a meaningful improvement in pain and function compared with patients with peripheral neuropathic pain at 12-month follow-up. PMID: 29996953 [PubMed - as supplied by publisher]
Source: The Canadian Journal of Neurological Sciences - July 12, 2018 Category: Neurology Authors: Staudt MD, Clark AJ, Gordon AS, Lynch ME, Morley-Forster PK, Nathan H, Smyth C, Stitt LW, Toth C, Ware MA, Moulin DE Tags: Can J Neurol Sci Source Type: research